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Abstract
Deficient microbial stimulation of the immune system, caused by hygiene, may underly the
atopy and allergic asthma epidemic we are currently experiencing. Consistent with this
‘hygiene hypothesis’, research on immunotherapy of allergic diseases also centres on
bacteria-derived molecules (eg DNA immunostimulatory sequences) as adjuvants for
allergen-specific type 1 immune responses. If we understood how certain microbes
physiologically ‘educate’ our immune system to interact safely with environmental
nonmicrobial antigens, we might be able to learn to mimic their beneficial actions.
Programmed ‘immunoeducation’ would consist of safe administration, by the correct route,
dose and timing, of those microbial stimuli that are necessary to ‘train’ the developing
mucosal immune system and to maintain an appropriate homeostatic equilibrium between its
components. Overall, this would result in a prevention of atopy that is not limited to certain
specific allergens. Although such a strategy is far beyond our present potential, it may in
principle revert the epidemic trend of atopy and allergic asthma without jeopardizing the fight
against infectious diseases.
Keywords: allergy, asthma, DNA immunostimulatory sequences, epidemiology, lactobacilli, lipopolysaccharide,
mycobacteria, prevention, therapy
Received: 30 June 2000
Revisions requested: 30 August 2000
Revisions received: 8 September 2000
Accepted: 8 September 2000
Published: 25 October 2000
Respir Res 2000, 1:129–132
The electronic version of this article can be found online at
http://respiratory-research.com/content/1/3/129
© Current Science Ltd (Print ISSN 1465-9921; Online ISSN 1465-993X)
http://respiratory-research.com/content/1/3/129
Introduction
Allergic asthma is on the increase in Western countries,
as are efforts to identify the reasons for this increase [1].
This trend is part of a generalized increase in prevalence
of atopic conditions that are characterized by mucosal
eosinophilic inflammation, such as allergic rhinoconjunc-
tivitis and atopic eczema [1,2]. The allergy ‘epidemic’
appears to parallel the overly hygienic conditions that are
typical of affluent societies [3–5]. Hence, the hygiene
hypothesis has been suggested. According to this
hypothesis, changing interactions between humans and
microbes of their ecosystem alter the immune balance at
mucosal level between type 1 (Th1, Tcl) and type 2 (Th2,
Tc2) immunity, thereby predisposing to atopic diseases
[5,6], including allergic asthma. Partially deprived of
appropriate microbial stimulation, type 1 immune mecha-
nisms would no longer downregulate the hypersensitivity-
and allergy-causing type 2 response to a sufficient
degree [1,5–11].
Although the hygiene hypothesis remains a hypothesis,
it raises questions. Must we go back to living in ‘dirty’Respiratory Research    Vol 1 No 3 Matricardi and Bonini
conditions? Are allergy and asthma an unavoidable price
that westernized societies must pay for the decline in mor-
bidity and mortality from infectious diseases?
Will ‘poor’ hygiene cure asthma?
The answer to this provocative question is ‘no’. Many res-
piratory infections induce wheezing, and many cases of
wheezing that are linked to recurrent respiratory infections
are labelled ‘asthma’ or are perceived as such [12]. Some
respiratory viruses (eg respiratory syncytial virus) induce
asthma in predisposed individuals [13], whereas others
(eg rhinoviruses) exacerbate pre-existing atopic bronchial
inflammation [14].
The rising trend in severe asthma cases in poor, and
hence supposedly less hygienic, urban areas of US cities
(‘inner city asthma’) appears to refute the hygiene hypoth-
esis [15]. Therefore, the words ‘dirty’ or ‘hygiene’ are too
generic to be used to label environments that facilitate or
protect against allergy. We must still learn whether and
what kind of hygienic measures cause atopy, and generic
antihygienic procedures would obviously facilitate the
spread of infectious diseases.
By contrast, the traditional lifestyle that is typical of
anthroposophic [16] and farming communities [17]
appears highly protective, given the very low prevalence
of respiratory allergies in these groups. However, it
remains to be established whether the lower prevalence
of atopy is due to higher exposure to microbes or to
other hallmarks of a rural lifestyle [18]. Less indirect
support for the hygiene hypothesis came from epidemio-
logical studies of Italian military cadets [19,20], which
showed that exposure to food-borne and orofaecal infec-
tions, but not to air-borne viruses, was inversely associ-
ated with respiratory allergies. These serological studies
support the notion that a high turnover of ingested
microbes (mainly saprophytic, commensal and pathogen
bacteria) at mucosal surfaces, in particular the gut
mucosa, may ‘educate’ our mucosal immune system to
interact safely with nonmicrobial antigens [21–24]. This
would explain why the children of farmers and anthropo-
sophic communities are protected against bronchial
allergy and other atopic diseases [16,17,22,25]. Inter-
estingly, the concentration of exogenous lipopolysaccha-
ride in house dust was inversely related to atopy among
infants at risk for asthma [26]. This suggests that not
only ingested bacteria, but also bacterial immunostimu-
lating substances from inhalable sources could also
afford protection against allergy.
Given these premises, we may ask if children living in US
inner cities are exposed to a sufficiently diversified set of
bacteria and if they eat sufficiently contaminated food. It
would be interesting to determine the magnitude of expo-
sure to orofaecal and food-borne infections [22], and to
saprophytic bacteria-contaminated soil [11], in inner cities.
It is tempting to speculate that allergic children living in
those ‘unhygienic’ areas inhale and ingest a different kind,
variety and amount of bacteria compared with children of
farmers and anthroposophic families, who have access to
natural soil and eat only biologically treated food (fresh
vegetables and farm products).
Bacteria and bacterial substances that may
prevent atopy
To exert an atopy-preventing effect, it is thought microbes
must be present where and when allergen uptake, pro-
cessing and presentation to T cells occur [9,10]. Appro-
priate bacteria would act as natural Th1 ‘adjuvants’
during the priming of T cells against newly encountered
environmental antigens. Facultative and professional
antigen-presenting cells (dendritic cells) may be the
target of a microbial bystander effect, that may dictate the
pattern of accessory molecules and cytokines, and modu-
late the outcome (Th1- or Th2-like) of the allergen-spe-
cific T-cell response [9,27].
At least five kinds of bacteria or bacterial substances are
being examined for their proven or alleged atopy-prevent-
ing effect, and these are discussed below.
Immunostimulatory sequences
Short immunostimulatory DNA sequences with CpG
motifs are 20 times as frequent in bacterial DNA as in
mammalian DNA [28]. Immunostimulatory sequences are
among the strongest of the known Th1-stimulating adju-
vants; they suppress IgE responses and eosinophilic
recruitment  in vivo, and prevent allergic asthma in animal
models [29]. Adjuvant DNA immunostimulatory sequences
can provide part of the immunostimulatory effects of Fre-
und’s adjuvant without the severe inflammatory and toxic
side effects attributed to the paraffin oil and mycobacterial
cell wall products [30].
Mycobacterium vaccae
An inverse association between atopy and reactivity to
tuberculin among Japanese children suggested that
exposure to environmental mycobacteria inhibits atopic
sensitization through stimulation of type 1 immunity [31],
as suggested by animal experimental models [32].
Humans have been always exposed to mycobacteria,
mainly through natural soil dust and contaminated food.
Rook and Stanford [11] proposed that mycobacteria
might therefore have influenced the evolution of the
immune system because they have been ubiquitous
throughout mammalian phylogeny. Consequently, the
concrete paving of modern cities and food hygiene may
have deprived westernized populations of a fundamental
stimulus for the maturation of their mucosa-associated
lymphoid tissue, thus contributing to the asthma epi-
demic [6,11,20].c
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Lipopolysaccharide
Endotoxin from the cell wall of Gram-negative bacteria
promotes survival and maturation of dendritic cells [33]. It
is among the most potent stimuli for production of IL-12, a
key molecule in type 1 immunity, by these cells [34].
Lipopolysaccharide from gut commensal flora may provide
a major stimulus for postnatal maturation of dendritic cell
function at both peripheral tissue sites and central lym-
phoid compartments [9]. Thus, deficient stimulation by
Gram-negative bacteria in the gastrointestinal tract may
result in deficient maturation of antigen-presenting cells
and lower propensity to develop Th1 responses toward
environmental antigens [9,23]. Inhalation of ‘exogenous’
endotoxin from house dust may protect against atopy [26],
but it should be noted that Gram-negative bacteria that
colonize the gastrointestinal tract are by far a greater
‘endogenous’ source of endotoxin. Interestingly, the gut
microflora of infants growing in developing countries is
characterized by early colonization, high turnover rate and
high strain diversity of Gram-negative bacteria (ie
Escherichia coli), suggesting a higher exposure to
endogenous lipopolysaccharide as compared with infants
reared in developed countries [24].
Lactobacillus spp
Allergic 2-year-old Swedish and Estonian children were
colonized less often by lactobacilli, and harboured higher
counts of aerobic bacteria (coliforms, Staphylococcus
aureus) than did nonallergic children [21]. Lactobacilli
from human gastrointestinal mucosa are strong stimulators
of IL-12 production by mononuclear cells in vitro [35] and
of major histocompatibility class II molecules in vivo [36].
The ingestion of fermented vegetables, which are rich in
lactobacilli, has been associated with a lower risk of atopy
and allergies in children exposed to an anthroposophic
lifestyle [16]. Evidence that gut flora may affect the induc-
tion of oral tolerance has promoted calls for clinical trials
aimed at establishing whether lactobacilli-containing
preparations are useful in allergic diseases [37].
Oral bacterial extracts
Oral bacterial extracts have been claimed to stimulate
immune responses against recurrent airway infections, but
their therapeutic or preventive effect is far from proven
[38]. Some allergists administer these preparations empir-
ically as coadjuvants of oral allergen vaccines but, to our
knowledge, scientific trials to evaluate this approach have
not been performed.
‘Immunoeducation’: a novel strategy or an
utopian goal?
Bacteria or bacterial products are already being tested
against allergic diseases. Encouraging preliminary data
are coming from animal studies in which DNA immunos-
timulatory sequences are used as adjuvants with allergen
for allergen-specific immunotherapy, and from trials with
M vaccae (SRL172) administered before the pollination
period in patients affected by seasonal respiratory aller-
gies [39]. These strategies are aimed at reducing allergic
reactivity in patients and at treating or preventing sensitiza-
tion to single specific allergens. Hopefully, they may there-
fore improve our potential for immunotherapy or
immunoprophylaxis of sensitization toward some selected
allergens [40]; however, we would continue to observe a
high prevalence of atopic diseases among populations fol-
lowing a hygienic lifestyle, because it would be difficult to
immunize against any potential environmental or food aller-
genic molecules.
Conversely, if we understood how microbes ‘educate’ our
immune system we could perhaps learn to safely mimic
their beneficial effect. Programmed ‘immunoeducation’
would consist of safe administration, by the correct route
and at the correct dose and time schedule, of the variety
of microbial stimuli that are required by the mucosal
immune system during its development, and that are nec-
essary to maintain an appropriate equilibrium between its
components. This approach may be helpful in preventing
atopy with a more ‘physiological’ stimulation, without the
need of immunizing against all of the allergens that are
potentially encountered during a whole lifetime.
Conclusion
Homeostasis of the immune system is so complex and
microbial exposure is so diversified that, at the present
state of our knowledge, ‘immunoeducation’ is far beyond
our reach. More feasible and specific immunological thera-
pies or prophylactic measures may emerge from the
ongoing studies referred to above. Ultimately, although
poor hygiene will never cure asthma, the hygiene hypothe-
sis may result in new strategies in the fight against the
allergy and asthma epidemic.
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